

# Kena A Swanson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4018801/publications.pdf>

Version: 2024-02-01

24  
papers

22,767  
citations

279701

23  
h-index

552653

26  
g-index

36  
all docs

36  
docs citations

36  
times ranked

28749  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. <i>New England Journal of Medicine</i> , 2022, 386, 35-46.  | 13.9 | 431       |
| 2  | Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. <i>Science</i> , 2022, 375, 678-680.   | 6.0  | 303       |
| 3  | Modeling SARS-CoV-2: Comparative Pathology in Rhesus Macaque and Golden Syrian Hamster Models. <i>Toxicologic Pathology</i> , 2022, 50, 280-293.                                    | 0.9  | 21        |
| 4  | Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. <i>Cell Host and Microbe</i> , 2022, 30, 485-488.e3.                              | 5.1  | 80        |
| 5  | Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2022, 386, 1910-1921.  | 13.9 | 215       |
| 6  | BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, 41.  | 2.9  | 4         |
| 7  | Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy. <i>New England Journal of Medicine</i> , 2022, 386, 1615-1626.                                     | 13.9 | 78        |
| 8  | Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. <i>New England Journal of Medicine</i> , 2022, 386, 2377-2386.   | 13.9 | 54        |
| 9  | Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. <i>Nature Communications</i> , 2022, 13, .  | 5.8  | 63        |
| 10 | Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. <i>Emerging Microbes and Infections</i> , 2022, 11, 1828-1832. | 3.0  | 32        |
| 11 | BNT162b vaccines protect rhesus macaques from SARS-CoV-2. <i>Nature</i> , 2021, 592, 283-289.   | 13.7 | 494       |
| 12 | Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. <i>Nature Medicine</i> , 2021, 27, 620-621.                          | 15.2 | 562       |
| 13 | The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. <i>Npj Vaccines</i> , 2021, 6, 44.   | 2.9  | 36        |
| 14 | Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. <i>Science</i> , 2021, 371, 1152-1153.  | 6.0  | 485       |
| 15 | Neutralizing Activity of BNT162b2-Elicited Serum. <i>New England Journal of Medicine</i> , 2021, 384, 1466-1468.  | 13.9 | 528       |
| 16 | BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. <i>Nature</i> , 2021, 596, 273-275.  | 13.7 | 318       |
| 17 | BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. <i>New England Journal of Medicine</i> , 2021, 385, 472-474.  | 13.9 | 93        |
| 18 | Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. <i>New England Journal of Medicine</i> , 2021, 385, 239-250.                                  | 13.9 | 709       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. <i>New England Journal of Medicine</i> , 2021, 385, 1627-1629.                     | 13.9 | 346       |
| 20 | Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. <i>New England Journal of Medicine</i> , 2021, 385, 1761-1773. | 13.9 | 1,090     |
| 21 | COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. <i>Nature</i> , 2020, 586, 594-599.                             | 13.7 | 1,520     |
| 22 | Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. <i>New England Journal of Medicine</i> , 2020, 383, 2439-2450.     | 13.9 | 2,107     |
| 23 | Phase III study of COVID-19 RNA vaccine BNT162b1 in adults. <i>Nature</i> , 2020, 586, 589-593.  | 13.7 | 1,197     |
| 24 | Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2020, 383, 2603-2615.                  | 13.9 | 11,472    |